Lawyer accuses J&J of negligence in Topamax case; FDA pulls another Wellbutrin generic on lack of bioequivalence;

@FiercePharma: Top news online yesterday: J&J hikes earnings forecast on pharma's superhero sales flight. Story | Follow @FiercePharma

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Look out, Vivus--Eisai to double Belviq sales force by December 2013. Release | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) was negligent in warning expectant mothers of the risk of birth defects with its seizure drug Topamax, a lawyer for one woman said, as a trial over her son's cleft palate began. Report

> The FDA said another generic version of Wellbutrin XL, this one from Actavis ($ACT), would be pulled off the market because it is not bioequivalent to the branded drug. Report

> Health Canada said it will better communicate the risks of recalled drugs after a report criticized its handling of Apotex's recall of its birth control pill Alysena 28. Report

> The U.S. Supreme Court declined to hear the case of a woman who sought to hold Hospira ($HSP) liable for a shortage of its injectable drug Aquasol A. Report

> Russia's pharmaceuticals sales are expected to grow by 11% this year, to $130.4 billion, the market research firm Business Monitor says. Report

> Florida prison officials executed a man using the sedative midazolam hydrochloride as part of a three-drug cocktail; the drug had not been used in previous executions. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceMedDev

> TB Dx maker Oxford Immunotec to pursue IPO path. Report

> Myriad vs. Quest over BRCA testing: It's getting serious. More

> Abbott posts med tech growth thanks to diagnostics, dealmaking. Story

Biotech News

@FierceBiotech: ICYMI yesterday: The top Phase III R&D setbacks of 2013. Feature | Follow @FierceBiotech

@JohnCFierce: Third Rock startup banks $20M to fuel next leg of CNS drug development journey. News | Follow @JohnCFierce

@DamianFierce: St. Jude boosts profits as job cuts, M&A pay off. Article | Follow @DamianFierce

@EmilyMFierce: Georgetown University Medical Center researchers find a vegetable-based compound that protects against side effects of radiation therapy. Article from FierceBiotech Research | Follow @EmilyMFierce

> Is Eli Lilly about to start cutting its blockbuster R&D budget? More

> MedImmune leads $12.5M round for new drug aimed at big chemo market. Article

> Sanofi, Regeneron take the lead in blockbuster PhIII race of PCSK9 drugs. Story

Biomarkers News

> Biomarker differentiates ADHD subtypes, offers clues for treatment. Article

> Amgen taps KineMed for Alzheimer's biomarkers. Report

> Skin may conceal a viable Parkinson's biomarker. Story

Drug Delivery News

@MichaelGFierce: AstraZeneca teams with Taris to research bladder cancer delivery device. Story | Follow @MichaelGFierce

> Mini-pancreas grown from stem cells has implications for future insulin delivery. More

> Cell membrane models 'written' on graphene provide drug-delivery model. Item

> Study: Synthetic RNA conjugates target, silence bacteria's genetic material. Article

> Nanoparticle hydrogel heats up to release drugs in active cartilage. Story

Diagnostics News

@MarkHFierce: Smith & Nephew will handle U.S. distribution of a women's care diagnostic device developed by Femasys. Story | Follow @MarkHFierce

> Applied Proteomics to develop pancreatic and colon cancer Dx with German research institute. More

> Quest preemptively sues Myriad to ensure new BRCA test avoids patent violation. Report

> CardioDx's proposed $86.2M IPO will aid marketing and insurance coverage efforts. Story

> New blood test screens for irritable bowel syndrome. Article

> Mount Sinai's Icahn School of Medicine jumps into Dx, drug development. Item

And Finally... U.S. regulators are set to consider whether a "three-parent" reproductive technique should be tested as a way to keep genetic defects from passing from mothers to children. Report

Suggested Articles

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.

EU health commissioner Stella Kyriakides reportedly spoke with Gilead execs to iron out a deal to secure remdesivir supply for 16 EU countries.

Under a $1.6 billion deal with the U.S. government, Novavax has pledged to start producing 100 million doses of a COVID-19 vaccine later this year.